Brief: Pfizer And Astellas’ Padcev Plus Keytruda Shows Long-Term Efficacy In First-Line Treatment Of Locally Advanced Or Metastatic Urothelial Cancer
10/02/2025 22:31
Feb 10 (Reuters) - Astellas Pharma Inc 4503.T :
* PFIZER AND ASTELLAS’ PADCEV® (ENFORTUMAB VEDOTIN-EJFV)
PLUS
KEYTRUDA® (PEMBROLIZUMAB) SHOWS LONG-TERM EFFICACY IN FIRST-LINE
TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER
(LA/MUC)
* ASTELLAS PHARMA INC: NO NEW SAFETY SIGNALS IDENTIFIED FROM
PHASE
3 EV-302 TRIAL
* ASTELLAS PHARMA INC: ENFORTUMAB VEDOTIN PLUS PEMBROLIZUMAB
CONTINUES TO DEMONSTRATE SUPERIOR EFFICACY VERSUS CHEMOTHERAPY
IN BROAD POPULATION
Source text: ID:nBwbjwWb8a
Further company coverage: 4503.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn